Cervical cancer testing among women aged 30-49 years in the WHO European Region.
Journal
European journal of public health
ISSN: 1464-360X
Titre abrégé: Eur J Public Health
Pays: England
ID NLM: 9204966
Informations de publication
Date de publication:
11 10 2021
11 10 2021
Historique:
pubmed:
8
9
2021
medline:
11
11
2021
entrez:
7
9
2021
Statut:
ppublish
Résumé
Screening programs play an important role in a comprehensive strategy to prevent cervical cancer, a leading cause of death among women of reproductive age. Unfortunately, there is a dearth of information about rates of cervical cancer testing, particularly in Eastern Europe and Central Asia where levels of cervical cancer are among the highest in the WHO European Region. The purpose of this article is to report on the lifetime prevalence of cervical cancer testing among females aged 30-49 years from across the WHO European region, and to describe high-level geographic and socioeconomic differences. We used data from the European Health Information Survey and the WHO STEPwise approach to Surveillance survey to calculate the proportions of women who were tested for cervical cancer. The percentage of tested women ranged from 11.7% in Azerbaijan to 98.4% in Finland, with the lowest percentages observed in Azerbaijan, Tajikistan and Uzbekistan. Testing was lower in Eastern Europe (compared to Western Europe), among low-income countries and among women with lower levels of education. Effective cervical cancer screening programs are one part of a larger strategy, which must also include national scale-up of human papilloma virus vaccination, screening and treatment.
Sections du résumé
BACKGROUND
Screening programs play an important role in a comprehensive strategy to prevent cervical cancer, a leading cause of death among women of reproductive age. Unfortunately, there is a dearth of information about rates of cervical cancer testing, particularly in Eastern Europe and Central Asia where levels of cervical cancer are among the highest in the WHO European Region. The purpose of this article is to report on the lifetime prevalence of cervical cancer testing among females aged 30-49 years from across the WHO European region, and to describe high-level geographic and socioeconomic differences.
METHODS
We used data from the European Health Information Survey and the WHO STEPwise approach to Surveillance survey to calculate the proportions of women who were tested for cervical cancer.
RESULTS
The percentage of tested women ranged from 11.7% in Azerbaijan to 98.4% in Finland, with the lowest percentages observed in Azerbaijan, Tajikistan and Uzbekistan. Testing was lower in Eastern Europe (compared to Western Europe), among low-income countries and among women with lower levels of education.
CONCLUSION
Effective cervical cancer screening programs are one part of a larger strategy, which must also include national scale-up of human papilloma virus vaccination, screening and treatment.
Identifiants
pubmed: 34491325
pii: 6365774
doi: 10.1093/eurpub/ckab100
pmc: PMC8514175
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
884-889Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Organisme : Department of Health
Pays : United Kingdom
Informations de copyright
© World Health Organization, [2021]. All rights reserved. The World Health Organization has granted the Publisher permission for the reproduction of this article. This is an Open Access article distributed under the terms of the Creative Commons Attribution 3.0 IGO License (https://creativecommons.org/licenses/by/3.0/igo/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Références
BMJ. 2009 Jul 28;339:b2569
pubmed: 19638649
PLoS One. 2012;7(11):e48834
pubmed: 23155413
Am J Public Health. 2016 Jan;106(1):74-8
pubmed: 26696288
Lancet. 2007 Sep 8;370(9590):890-907
pubmed: 17826171
Int J Cancer. 2014 Jul 1;135(1):204-13
pubmed: 24347441
PLoS Med. 2008 Jun 17;5(6):e132
pubmed: 18563963
Cancer Med. 2019 May;8(5):2524-2534
pubmed: 30993902
Lancet. 2020 Feb 22;395(10224):591-603
pubmed: 32007142
PLoS One. 2019 Nov 25;14(11):e0225667
pubmed: 31765426
Prev Med. 2012 Dec;55(6):587-96
pubmed: 23064024
Lancet. 2015 Aug 22;386(9995):743-800
pubmed: 26063472
J Med Screen. 2021 Mar;28(1):48-50
pubmed: 31980007
Lancet. 2017 Feb 25;389(10071):847-860
pubmed: 27814965
Cancer Epidemiol Biomarkers Prev. 2012 Sep;21(9):1423-33
pubmed: 22956728
Prev Med. 2015 Jun;75:56-63
pubmed: 25818232
Cancer Epidemiol. 2021 Aug;73:101944
pubmed: 33975255
Lancet Oncol. 2019 Mar;20(3):394-407
pubmed: 30795950